Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

68.85USD
1:31am IST
Change (% chg)

$1.48 (+2.20%)
Prev Close
$67.37
Open
$67.50
Day's High
$69.00
Day's Low
$67.37
Volume
4,368,435
Avg. Vol
3,025,655
52-wk High
$69.00
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  MRK.N Industry Sector
P/E (TTM): 35.16 30.93 32.76
EPS (TTM): 1.84 -- --
ROI: 6.58 15.07 14.61
ROE: 12.28 16.59 16.33

UPDATE 1-Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 Japan's Eisai Co Ltd on Thursday received U.S. approval for a therapy for previously untreated patients with a common form of liver cancer, paving the way for multibillion dollar sales.

12:55am IST

Merck profit beats, but Keytruda sales fail to impress

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy.

27 Jul 2018

UPDATE 4-Merck profit beats, but Keytruda sales fail to impress

* Keytruda sales edge past rival Opdivo's, analysts' estimate

27 Jul 2018

Merck's quarterly profit falls 12 pct

July 27 Drugmaker Merck & Co reported a 12.3 percent fall in quarterly profit on Friday, as research and development expenses rose.

27 Jul 2018

Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday posted better-than-expected second-quarter earnings and raised its full-year forecast on strong sales from its blockbuster cancer drug Opdivo and blood thinner Eliquis.

26 Jul 2018

Merck lowers prices of some drugs after Trump calls out industry

Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

20 Jul 2018

UPDATE 1-Merck lowers prices of some drugs after Trump calls out industry

July 19 Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

20 Jul 2018

Merck lowers prices of some drugs after Trump calls out industry

July 19 Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a little-used hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

20 Jul 2018

U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

28 Jun 2018

CORRECTED-UPDATE 1-U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON, June 28 The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

28 Jun 2018

Competitors

Earnings vs. Estimates